Matches in SemOpenAlex for { <https://semopenalex.org/work/W2374764734> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2374764734 abstract "Objective To investigate the efficacy and safety of peginterferon alfa-2b as well as compliance improvement for the treatment of peginterferon alfa-2a non-responders or non-compliant patients.Methods All 11 peginterferon alfa-2a non-responders or no-compliant or relapsed patients were from Shanghai Public Health Center and other hospitals.Real-time RT-PCR technique was used to test serum HCV RNA and non-encoding region PCR amplification sequencing to analyze HCV genotype.All patients enrolled were treated by peginterferon alfa-2b and ribavirin combination therapy.Results Genotype analysis:7 cases were infected with genotype 1b HCV,1 case with genotype 2a,1 case with genotype 2b and 2 cases were not tested.Four patients were non-responders,six patients were non-compliant(4 of 6 were due to severe bone marrow suppression),one patient was relapser of peginterferon alfa-2a.Retreatment with peginterferon alfa-2b should adhere to full course and at least 80% of recommended dosage.All 4 peginterferon alfa-2a non-responders had end of treatment response,and 3 patients achieved sustained virologic response(SVR),one patient relapsed,respectively.Among six non-compliant patients,four patients finished full course treatment and 3 of them achieved SVR,one patient had no response.One patient discontinued therapy due to severe cardiac disease and one was still in therapy.One relapsed patient achieved SVR.Three of 7 patients who achieved SVR had rapid virologic response and all 7 patients had early virologic response.Conclusions Patients who failed in peginterferon alfa-2a treatment due to lack of response,severe side effects or relapsed can be retreated successfully by peginterferon alfa-2b unless the patient had severe cardiac disease.Retreatment with peginterferon alfa-2b should adhere to full course and at least 80% dosage and the response rate could be raised." @default.
- W2374764734 created "2016-06-24" @default.
- W2374764734 creator A5079647685 @default.
- W2374764734 date "2007-01-01" @default.
- W2374764734 modified "2023-09-23" @default.
- W2374764734 title "Peginterteron alfa-2b treatment of chronic incurable hepatitis C correspond is a substitution of peginterferon alfa-2a" @default.
- W2374764734 hasPublicationYear "2007" @default.
- W2374764734 type Work @default.
- W2374764734 sameAs 2374764734 @default.
- W2374764734 citedByCount "0" @default.
- W2374764734 crossrefType "journal-article" @default.
- W2374764734 hasAuthorship W2374764734A5079647685 @default.
- W2374764734 hasConcept C104317684 @default.
- W2374764734 hasConcept C126322002 @default.
- W2374764734 hasConcept C135763542 @default.
- W2374764734 hasConcept C185592680 @default.
- W2374764734 hasConcept C203014093 @default.
- W2374764734 hasConcept C2522874641 @default.
- W2374764734 hasConcept C2776235749 @default.
- W2374764734 hasConcept C2776455275 @default.
- W2374764734 hasConcept C2780040827 @default.
- W2374764734 hasConcept C3020491458 @default.
- W2374764734 hasConcept C55493867 @default.
- W2374764734 hasConcept C71924100 @default.
- W2374764734 hasConcept C90924648 @default.
- W2374764734 hasConceptScore W2374764734C104317684 @default.
- W2374764734 hasConceptScore W2374764734C126322002 @default.
- W2374764734 hasConceptScore W2374764734C135763542 @default.
- W2374764734 hasConceptScore W2374764734C185592680 @default.
- W2374764734 hasConceptScore W2374764734C203014093 @default.
- W2374764734 hasConceptScore W2374764734C2522874641 @default.
- W2374764734 hasConceptScore W2374764734C2776235749 @default.
- W2374764734 hasConceptScore W2374764734C2776455275 @default.
- W2374764734 hasConceptScore W2374764734C2780040827 @default.
- W2374764734 hasConceptScore W2374764734C3020491458 @default.
- W2374764734 hasConceptScore W2374764734C55493867 @default.
- W2374764734 hasConceptScore W2374764734C71924100 @default.
- W2374764734 hasConceptScore W2374764734C90924648 @default.
- W2374764734 hasLocation W23747647341 @default.
- W2374764734 hasOpenAccess W2374764734 @default.
- W2374764734 hasPrimaryLocation W23747647341 @default.
- W2374764734 hasRelatedWork W1802345175 @default.
- W2374764734 hasRelatedWork W1969254356 @default.
- W2374764734 hasRelatedWork W1989022528 @default.
- W2374764734 hasRelatedWork W2014171438 @default.
- W2374764734 hasRelatedWork W2015571005 @default.
- W2374764734 hasRelatedWork W2016559540 @default.
- W2374764734 hasRelatedWork W2018446644 @default.
- W2374764734 hasRelatedWork W2060691408 @default.
- W2374764734 hasRelatedWork W2077552565 @default.
- W2374764734 hasRelatedWork W2080288831 @default.
- W2374764734 hasRelatedWork W2090037050 @default.
- W2374764734 hasRelatedWork W2098036743 @default.
- W2374764734 hasRelatedWork W2107175809 @default.
- W2374764734 hasRelatedWork W2132503465 @default.
- W2374764734 hasRelatedWork W2146956830 @default.
- W2374764734 hasRelatedWork W2331499216 @default.
- W2374764734 hasRelatedWork W2373586664 @default.
- W2374764734 hasRelatedWork W2376502568 @default.
- W2374764734 hasRelatedWork W2783978214 @default.
- W2374764734 hasRelatedWork W2978151643 @default.
- W2374764734 isParatext "false" @default.
- W2374764734 isRetracted "false" @default.
- W2374764734 magId "2374764734" @default.
- W2374764734 workType "article" @default.